Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 2
1962 2
1963 2
1965 1
1966 1
1967 3
1968 4
1969 5
1970 3
1971 5
1972 6
1973 2
1974 6
1975 12
1976 17
1977 9
1978 13
1979 17
1980 24
1981 15
1982 26
1983 28
1984 13
1985 24
1986 32
1987 39
1988 33
1989 35
1990 36
1991 25
1992 39
1993 41
1994 25
1995 30
1996 33
1997 42
1998 51
1999 32
2000 49
2001 49
2002 49
2003 49
2004 44
2005 53
2006 70
2007 81
2008 84
2009 80
2010 114
2011 111
2012 130
2013 138
2014 136
2015 114
2016 128
2017 106
2018 135
2019 137
2020 157
2021 159
2022 137
2023 133
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

2,920 results

Results by year

Filters applied: . Clear all
Page 1
Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology.
Sinnathamby ES, Issa PP, Roberts L, Norwood H, Malone K, Vemulapalli H, Ahmadzadeh S, Cornett EM, Shekoohi S, Kaye AD. Sinnathamby ES, et al. Adv Ther. 2023 Mar;40(3):814-827. doi: 10.1007/s12325-022-02401-0. Epub 2023 Jan 7. Adv Ther. 2023. PMID: 36609679 Free PMC article. Review.
Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a mutation in the C1 esterase inhibitor gene. HAE affects 1/50,000 people worldwide. ...Current guidelines now recommend subdividing hereditary angioedema with normal C1 esteras
Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a mutation in the C1 esterase inhibitor gene. H …
Cinryze (C1-inhibitor) for the treatment of hereditary angioedema.
Gompels MM, Lock RJ. Gompels MM, et al. Expert Rev Clin Immunol. 2011 Sep;7(5):569-73. doi: 10.1586/eci.11.50. Expert Rev Clin Immunol. 2011. PMID: 21895469 Review.
Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema. In a double-blind placebo-controlled crossover trial to evaluate Cinryze as prophylaxis, the
Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylac
Treatment of Hereditary Angioedema.
Caballero T. Caballero T. J Investig Allergol Clin Immunol. 2021 Feb;31(1):1-16. doi: 10.18176/jiaci.0653. J Investig Allergol Clin Immunol. 2021. PMID: 33602658 Free article. Review.
Hereditary angioedema due to C1-esterase inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant disease. ...Purified plasma-derived human C1 esterase inhibitor concentrate is the treatment of choice for short-term prophylax …
Hereditary angioedema due to C1-esterase inhibitor deficiency (C1-INH-HAE) is a rare autosomal dominant disease. …
Hereditary and acquired angioedema.
Patel G, Pongracic JA. Patel G, et al. Allergy Asthma Proc. 2019 Nov 1;40(6):441-445. doi: 10.2500/aap.2019.40.4267. Allergy Asthma Proc. 2019. PMID: 31690390 Review.
Hereditary angioedema (HAE) is an autosomal dominant disorder defined by a deficiency of functional C1 esterase inhibitor (C1-INH). Acquired angioedema is due to either consumption (type 1) or inactivation (type 2) of CI-INH. ...On-demand therapy optio …
Hereditary angioedema (HAE) is an autosomal dominant disorder defined by a deficiency of functional C1 esterase inhibitor
C1-esterase inhibitor (Cinryze()) use in the treatment of pediatric hereditary angioedema.
Gupta R, Balduzzi J, Davis-Lorton M. Gupta R, et al. Immunotherapy. 2018 Jun;10(8):635-642. doi: 10.2217/imt-2017-0049. Epub 2018 Mar 23. Immunotherapy. 2018. PMID: 29569504 Review.
HAE often presents within the first or second decade of life, with attacks increasing in both frequency and severity over time. First-line therapies exert their action by replacing C1 inhibitor (C1-INH) or via blocking the production or function of bradykinin …
HAE often presents within the first or second decade of life, with attacks increasing in both frequency and severity over time. First-line t …
Nanofiltered human C1 inhibitor concentrate (Cinryze): in hereditary angioedema.
Lyseng-Williamson KA. Lyseng-Williamson KA. BioDrugs. 2011 Oct 1;25(5):317-27. doi: 10.2165/11208390-000000000-00000. BioDrugs. 2011. PMID: 21942916 Review.
Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE). ...Intravenous C1-INH NF concent …
Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze) is used as a direct replacement of …
Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N, Frese M, Smertina E, Mere P, Katelaris C, Mills K. Beard N, et al. Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article. Review.
People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1 esterase inhibitor (C1-INH) protein; people with Type II HAE (approximately 20% of all cases) may have normal C1-INH concentrations, but, due to g …
People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1 esterase inhibitor (C1
Successful treatment with Cinryze replacement therapy of a pregnant patient with hereditary angioedema: a case report.
Kardum Ž, Prus V, Milas Ahić J, Kardum D. Kardum Ž, et al. J Med Case Rep. 2021 Jan 24;15(1):20. doi: 10.1186/s13256-020-02622-3. J Med Case Rep. 2021. PMID: 33485376 Free PMC article.
CASE PRESENTATION: We present a female Caucasian patient with pre-existing HAE and disease exacerbations during pregnancy, requiring prophylactic use of plasma-derived C1 inhibitor concentrate. She was treated with Cinryze replacement therapy throughout the p …
CASE PRESENTATION: We present a female Caucasian patient with pre-existing HAE and disease exacerbations during pregnancy, requiring prophyl …
Hereditary Angio-Oedema for Dermatologists.
Bygum A. Bygum A. Dermatology. 2019;235(4):263-275. doi: 10.1159/000500196. Epub 2019 Jun 5. Dermatology. 2019. PMID: 31167185 Free article. Review.
Classically, patients with HAE have a quantitative or qualitative deficiency of the C1 inhibitor (C1INH) due to different mutations in SERPING1, although a new subtype with normal C1INH has been recognised more recently. ...
Classically, patients with HAE have a quantitative or qualitative deficiency of the C1 inhibitor (C1INH) due to different muta …
Acquired C1 Inhibitor Deficiency.
Otani IM, Banerji A. Otani IM, et al. Immunol Allergy Clin North Am. 2017 Aug;37(3):497-511. doi: 10.1016/j.iac.2017.03.002. Epub 2017 May 15. Immunol Allergy Clin North Am. 2017. PMID: 28687105 Review.
Acquired angioedema due to C1-INH deficiency (C1-INH-AAE) can occur when there are acquired (not inherited) deficiencies of C1-INH. A quantitative or functional C1-INH deficiency with negative family history and low C1q is diagnostic of C1-INH-A …
Acquired angioedema due to C1-INH deficiency (C1-INH-AAE) can occur when there are acquired (not inherited) deficiencies of …
2,920 results